Novozymes A/S (CPH:NSIS.B)
Denmark · Delayed Price · Currency is DKK 350.60
+8.60 (2.51%)
At close: Mar 20, 2026
Novozymes Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,158 | 3,834 | 2,402 | 2,360 | 2,011 | |
Revenue Growth (YoY) | 8.45% | 59.58% | 1.80% | 17.36% | 6.82% |
Cost of Revenue | 1,852 | 1,840 | 1,097 | 1,071 | 849.06 |
Gross Profit | 2,305 | 1,993 | 1,305 | 1,289 | 1,162 |
Selling, General & Admin | 911.8 | 765.5 | 446.1 | 433.3 | 375.91 |
Research & Development | 448.5 | 413.2 | 270.7 | 267 | 266.57 |
Other Operating Expenses | -16.7 | -28.2 | -22.9 | -10.08 | -8.88 |
Operating Expenses | 1,344 | 1,151 | 693.9 | 686.85 | 638.04 |
Operating Income | 961.7 | 842.9 | 610.9 | 602.42 | 523.72 |
Interest Expense | -68.3 | -76.4 | -6.5 | -13.71 | -13.72 |
Interest & Investment Income | 21 | 26.9 | - | 2.42 | 2.42 |
Earnings From Equity Investments | -6.5 | -3.5 | -2.4 | -0.94 | -0.54 |
Currency Exchange Gain (Loss) | -19.3 | -5.7 | - | -44.37 | -0.54 |
Other Non Operating Income (Expenses) | -0.2 | -20.1 | - | -13.31 | -2.69 |
EBT Excluding Unusual Items | 888.4 | 764.1 | 602 | 532.52 | 508.66 |
Merger & Restructuring Charges | -126.4 | -332.3 | -73.3 | -9.14 | - |
Gain (Loss) on Sale of Investments | - | -5.1 | - | 62.92 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 16.41 |
Asset Writedown | -15.3 | -22.3 | - | -3.76 | -5.65 |
Other Unusual Items | -3.3 | 12.7 | -4 | 29.98 | 8.34 |
Pretax Income | 743.4 | 417.1 | 524.7 | 612.51 | 527.76 |
Income Tax Expense | 159.8 | 111.3 | 116.8 | 116.96 | 104.77 |
Earnings From Continuing Operations | 583.6 | 305.8 | 407.9 | 495.55 | 422.99 |
Minority Interest in Earnings | - | - | -2 | -1.34 | 0.13 |
Net Income | 583.6 | 305.8 | 405.9 | 494.2 | 423.12 |
Net Income to Common | 583.6 | 305.8 | 405.9 | 494.2 | 423.12 |
Net Income Growth | 90.84% | -24.66% | -17.87% | 16.80% | 11.48% |
Shares Outstanding (Basic) | 467 | 278 | 276 | 277 | 278 |
Shares Outstanding (Diluted) | 467 | 278 | 278 | 279 | 280 |
Shares Change (YoY) | 68.00% | - | -0.30% | -0.53% | -0.64% |
EPS (Basic) | 1.25 | 1.10 | 1.47 | 1.79 | 1.52 |
EPS (Diluted) | 1.25 | 0.67 | 1.46 | 1.77 | 1.51 |
EPS Growth | 86.57% | -54.11% | -17.67% | 17.41% | 12.20% |
Free Cash Flow | 811.7 | 681.6 | 308 | 167.51 | 402.27 |
Free Cash Flow Per Share | 1.74 | 2.45 | 1.11 | 0.60 | 1.44 |
Dividend Per Share | 0.870 | 0.830 | - | 0.807 | 0.740 |
Dividend Growth | 4.86% | - | - | 9.05% | 4.88% |
Gross Margin | 55.45% | 52.00% | 54.32% | 54.63% | 57.77% |
Operating Margin | 23.13% | 21.99% | 25.43% | 25.53% | 26.05% |
Profit Margin | 14.04% | 7.98% | 16.90% | 20.94% | 21.04% |
Free Cash Flow Margin | 19.52% | 17.78% | 12.82% | 7.10% | 20.00% |
EBITDA | 1,537 | 1,387 | 797.3 | 769.13 | 680.68 |
EBITDA Margin | 36.96% | 36.18% | 33.19% | 32.59% | 33.85% |
D&A For EBITDA | 574.8 | 544.1 | 186.4 | 166.71 | 156.96 |
EBIT | 961.7 | 842.9 | 610.9 | 602.42 | 523.72 |
EBIT Margin | 23.13% | 21.99% | 25.43% | 25.53% | 26.05% |
Effective Tax Rate | 21.50% | 26.68% | 22.26% | 19.10% | 19.85% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.